2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 667

Comparison of Patient and Provider Assessments of Response to Therapy for Psoriatic Arthritis
Abstract Number: 668

Pasdas, Cpdai and MDA Evolution in the First 6 Months after Diagnosis of Early Psoriatic Arthritis Patients: Results of the Depar Study
Abstract Number: 669

Assessment of Spinal Mobility in Axial Spondyloarthritis: First Validation Steps of a New Electronic Quantification Tool
Abstract Number: 670

Evaluation of the Predictive Value of Non-Specific Musculoskeletal Symptoms in Preclinical Phases of Psoriatic Arthritis
Abstract Number: 671

Discrepancy Between Patients and Physicians Acceptable Symptomatic States in Axial Spondyloarthritis: Findings from the RAPID-AxSpA Study
Abstract Number: 672

Validity of Ankylosing Spondylitis Diagnoses in the Health Improvement Network
Abstract Number: 673

Characterization of Psoriatic Arthritis [Psa] in a Large, Integrated Health Plan: Demographics, Referral Patterns and Care Management
Abstract Number: 674

Clinical Characteristics of Japanese Patients with Reactive Arthritis Induced By Intravesical BCG Therapy for Bladder Cancer: A 19 Years Two-Center Retrospective Study
Abstract Number: 675

Vitamin D Deficiency in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis. Results of the CARMA Study
Abstract Number: 676

What Proportion of Patients with Psa Fail to Achieve MDA Based on Patient Reported Outcomes? an Analysis from a Prospective, Observational Registry
Abstract Number: 677

Satisfaction in Psoriatic Arthritis Patients Despite Active Joint Disease
Abstract Number: 678

Clinical Characteristics and Disease Activity in Psoriatic Arthritis Patients with Dactylitis or Enthesitis: Results from Corrona Registry
Abstract Number: 679

Patients with Psoriatic Arthritis and Oligoarthritic Subtype Report Higher Disease Burden Than Patients with a Polyarthritic Pattern – Data from the German Collaborative Arthritis Centres
Abstract Number: 680

Variability over Time in Patient-Reported Outcome Measures in Patients with Ankylosing Spondylitis
Abstract Number: 681

Impact of Disease Duration on Patient Reported and Clinical Outcomes in Patients with Ankylosing Spondylitis Treated with Anti-TNF: An Analysis from a Prospective, Observational Registry

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].